Daunomycinone

Daunomycinone (NSC-109351) is a metabolite of Daunomycin (HY-13062A) and anticancer intermediate. Daunomycinone binds to nucleic acids synergistically with metal ions. Daunomycinone can be used in the research of leukemia[1][2][3][4][5].

Product Specifications

CAS Number

[21794-55-8]

Product Name Alternative

NSC-109351

UNSPSC

12352005

Hazard Statement

H301, H315, H317, H319, H334, H335, H340, H351, H360

Target

Drug Intermediate; Drug Metabolite

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/daunomycinone.html

Purity

98.89

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=CC(OC)=C1C2=O)C3=C2C(O)=C4[C@H](C[C@](C(C)=O)(CC4=C3O)O)O

Molecular Formula

C21H18O8

Molecular Weight

398.36

Precautions

H301, H315, H317, H319, H334, H335, H340, H351, H360

References & Citations

[1]Herman EH, et al. Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943) . Toxicol Appl Pharmacol. 1974 Mar;27 (3) :517-26.|[2]Tan C, et al. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20 (3) :333-53.|[3]Baer H H, et al. Synthesis and biological activity of (S) -2′-fluorodaunorubicin. Canadian journal of chemistry, 1988, 66 (1) : 187-190.|[4]Aligiannis N, et al. Synthesis and cytotoxic activity of a new potent daunomycinone derivative. Bioorg Med Chem Lett. 2002 Dec 16;12 (24) :3505-7.|[5]Mikelens P, et al. Metal ion participation in binding of daunomycinone, daunomycin, and adriamycin to nucleic acids. Bioinorganic Chemistry, 1978, 9 (5) : 441-452.